Pfizer Inc. $PFE Shares Acquired by Hancock Whitney Corp

Key Points

• Hancock Whitney Corp increased its stake in Pfizer Inc. by 32.8%, now holding 152,313 shares valued at approximately $3.86 million.
• Pfizer has reported a 10.3% year-over-year increase in revenue, reaching $14.65 billion, and earnings per share of $0.78, surpassing analyst expectations.
• The company announced a quarterly dividend of $0.43 per share, leading to an annualized dividend yield of 7.0%.

Hancock Whitney Corp increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 32.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 152,313 shares of the biopharmaceutical company's stock after buying an additional 37,646 shares during the quarter. Hancock Whitney Corp's holdings in Pfizer were worth $3,860,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. Clark Capital Management Group Inc. grew its holdings in shares of Pfizer by 3.1% during the 1st quarter. Clark Capital Management Group Inc. now owns 32,032 shares of the biopharmaceutical company's stock worth $812,000 after purchasing an additional 978 shares during the period. Bridgeway Capital Management LLC lifted its position in Pfizer by 8.5% during the first quarter. Bridgeway Capital Management LLC now owns 753,919 shares of the biopharmaceutical company's stock valued at $19,104,000 after buying an additional 58,916 shares in the last quarter. Belmont Capital LLC grew its stake in Pfizer by 72.0% during the first quarter. Belmont Capital LLC now owns 19,441 shares of the biopharmaceutical company's stock worth $493,000 after buying an additional 8,141 shares during the period. Alliancebernstein L.P. increased its position in shares of Pfizer by 0.9% in the first quarter. Alliancebernstein L.P. now owns 6,434,377 shares of the biopharmaceutical company's stock worth $163,047,000 after acquiring an additional 59,008 shares in the last quarter. Finally, Banque Transatlantique SA increased its position in shares of Pfizer by 2,787.1% in the first quarter. Banque Transatlantique SA now owns 1,934,531 shares of the biopharmaceutical company's stock worth $45,302,000 after acquiring an additional 1,867,525 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 1.1%

Shares of Pfizer stock opened at $24.51 on Friday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The stock has a market capitalization of $139.32 billion, a price-to-earnings ratio of 13.03, a PEG ratio of 0.88 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The business's 50 day simple moving average is $24.83 and its 200-day simple moving average is $24.36.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the previous year, the business earned $0.60 earnings per share. The company's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Jefferies Financial Group lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. HSBC lowered their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Finally, Berenberg Bank decreased their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Pfizer has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.